Stomach Cancer Treatment in Hyderabad
Reviewed May 2026 · Dr. Madhav Danthala
Stomach cancer is often diagnosed late in India because early symptoms mimic common indigestion. Dr. Madhav Danthala provides treatment planning, chemotherapy, targeted therapy, and immunotherapy at KIMS-Sunshine Hospitals, Begumpet, and Peoples Polyclinic, Manikonda.
When to See a Doctor
Most cases of indigestion are benign. The pattern that matters is when symptoms are new, persistent, or accompanied by other warning signs.
Dr. Danthala's Approach
Gastric cancer treatment in 2026 is increasingly precision-guided. Three principles shape every consultation.
-
Molecular profiling first
HER2, MSI, PD-L1, and CLDN18.2 are tested at diagnosis to guide therapy choice and identify candidates for targeted therapy or immunotherapy.
-
More than one path
For locally advanced gastric cancer, surgery-first vs perioperative chemotherapy vs newer immunotherapy combinations are all defensible — depending on tumour location and patient fitness.
-
Clear, structured communication
Every consult ends with a written summary of options, expected timelines, and the trade-offs each plan carries.
Treatment Options
Stomach cancer treatment is increasingly precision-guided. Surgery is the only curative modality for localised disease; systemic therapy choices depend on HER2, MSI, PD-L1, and CLDN18.2 status. Below are the major modalities.
Subtotal or total gastrectomy with D2 lymphadenectomy
For localised gastric cancer, the standard surgery is subtotal gastrectomy (for distal tumours) or total gastrectomy (for proximal/diffuse disease) with D2 lymph node dissection. Endoscopic submucosal dissection (ESD) is curative for very early mucosal tumours. Recovery from total gastrectomy involves dietary adaptation; nutritional support is part of standard post-operative care.
FLOT — fluorouracil, leucovorin, oxaliplatin, docetaxel
For locally advanced resectable disease, perioperative FLOT (4 cycles before and 4 cycles after surgery) has improved survival over older regimens (FLOT4 trial). For metastatic disease, FOLFOX or CAPOX is first-line. Sequential lines often follow with paclitaxel-based regimens. Triplet therapy is reserved for fit patients.
Trastuzumab, ramucirumab, zolbetuximab
For HER2+ disease (15-20%), trastuzumab combined with chemotherapy is first-line; trastuzumab deruxtecan (T-DXd) is approved for second-line. Ramucirumab (anti-VEGF) is added in second-line treatment. Zolbetuximab (anti-CLDN18.2) is approved for CLDN18.2+ HER2-negative gastric and gastroesophageal cancers — a major recent addition.
Pembrolizumab, nivolumab — first-line for PD-L1+ disease
For advanced gastric and gastroesophageal cancers, pembrolizumab combined with chemotherapy is first-line for PD-L1 CPS ≥ 1 (KEYNOTE-859). Nivolumab + chemotherapy is also approved (CheckMate 649). MSI-high tumours respond exceptionally well to immunotherapy as monotherapy. Each line of therapy is shaped by molecular profile.
Treatment is shaped by stage, molecular profile, and patient fitness. The list above is the menu. The right plan is built with the patient in the room.
Frequently Asked Questions
What are the warning signs of stomach cancer?
Persistent indigestion, feeling full quickly, unexplained weight loss, persistent upper abdominal pain, iron-deficiency anaemia, or difficulty swallowing. Most causes are benign, but persistence — especially over 45 — warrants endoscopic evaluation.
Should I get tested for H. pylori?
H. pylori is the most important modifiable risk factor for stomach cancer. Testing is recommended if you have persistent indigestion, ulcer-like symptoms, family history, or are from a high-prevalence region. Treatment with antibiotics significantly reduces long-term cancer risk. Hereditary syndromes also matter: Lynch syndrome connects gastric cancer to colorectal and ovarian risk, and CDH1 mutations link diffuse gastric cancer to lobular breast cancer — both warrant genetic counselling.
When should I have an upper GI endoscopy?
Endoscopy is underused in India given how common gastric cancer is. Indications: persistent indigestion, ulcer pain, unexplained weight loss, difficulty swallowing, iron-deficiency anaemia, family history. 20 minutes under sedation, no admission.
What is HER2-positive gastric cancer?
About 15-20% of stomach cancers over-express HER2. These respond well to anti-HER2 targeted therapy (trastuzumab) added to chemotherapy. Every advanced gastric cancer should be HER2-tested at diagnosis.
What does treatment involve?
Early-stage: surgery, often with perioperative chemotherapy. Advanced disease: chemotherapy plus targeted therapy (for HER2-positive or CLDN18.2-positive) or immunotherapy (for PD-L1 positive). Newer agents have significantly improved outcomes recently.
About Dr. Madhav Danthala
Dr. Madhav Danthala is a medical oncologist and hemato-oncologist practising at KIMS-Sunshine Hospitals, Begumpet and Peoples Polyclinic, Manikonda, Hyderabad. His clinical interests span breast, lung, gastrointestinal, gynaecologic, and head & neck cancers, with a focus on subtype-led treatment planning, second opinions, and shared decision-making. He has trained at premier oncology institutes and performed 300+ stem cell transplants.
Trusted guidelines & further reading
- ESMO — Cancer Guides for Patients European Society for Medical Oncology patient guides — freely accessible, evidence-based.
- ASCO / Cancer.Net — Stomach Cancer American Society of Clinical Oncology patient education portal.
- NCI / Cancer.gov — Gastric (Stomach) Cancer US National Cancer Institute clinical treatment summaries.
From our blog
- Your Mother's Medical History Is Your Screening Map CDH1 mutations link diffuse gastric cancer to lobular breast cancer; Lynch syndrome links it to colorectal and ovarian. Family history matters.
- The Two-Oncologist Rule: When to Get a Second Opinion Gastric cancer treatment is increasingly molecularly guided — CLDN18.2, HER2, MSI, PD-L1. A second opinion confirms profiling completeness.